|  | Total (n= 308) | Controls (n= 163) | GWX (n= 145) | P |
---|---|---|---|---|---|
Sex | Male | 186 (60%) | 98 (60%) | 88 (61%) | 0.92 |
Age | Mean (SD) | 60.6 (16.4) | 62.21 (15.6) | 58.7 (17.1) | 0.07 |
Diagnosis at admission | Respiratory | 40 (13%) | 24 (15%) | 16 (11%) | 0.33 |
 | Hepatic | 25 (8.1%) | 12 (7%) | 13 (9%) | 0.60 |
 | Cardiac | 77 (25%) | 44 (14.3%) | 33 (23%) | 0.39 |
 | GI | 43 (14%) | 23 (27%) | 20 (14%) | 0.93 |
 | Hematological | 5 (1.6%) | 1 (0.6%) | 4 (3%) | 0.19 |
 | Neurological | 33 (10.7%) | 23 (27%) | 10 (7%) | 0.04 |
 | Metabolic | 6 (2%) | 4 (2.5%) | 2 (1%) | 0.68 |
 | Sepsis | 40 (13%) | 29 (18%) | 11 (8%) | 0.01 |
 | Renal | 12 (4%) | 4 (2.5%) | 8 (6%) | 0.23 |
 | Vascular | 10 (3.25%) | 5 (3%) | 5 (3%) | 0.85 |
 | Trauma | 16 (5.2%) | 4 (2.5%) | 12 (8%) | 0.36 |
 | Musculoskeletal | 1 (0.3%) | 1 (0.6%) | 0 (0%) | 0.99 |
Apache III scores | Mean (SD) | 71.8 (13.6) | 72.3 (30.44) | 71.3 (30.8) | 0.77 |
Co-morbidities | Â | Â | Â | Â | Â |
 | Immune disease | 31 (10%) | 20 (12%) | 12 (8%) | 0.26 |
 | Immuno-suppression | 28 (9%) | 12 (7%) | 15 (10%) | 0.35 |
 | Chronic liver disease | 25 (8%) | 13 (8%) | 11 (8%) | 0.91 |
 | Metastases | 12 (4%) | 9 (6%) | 4 (3%) | 0.23 |
 | Leukaemia/myeloma/lymphoma | 9 (3%) | 6 (4%) | 4 (3%) | 0.14 |
 | Hepatic failure | 12 (4%) | 6 (4%) | 5 (3%) | 0.92 |
 | IDDM | 0 (0%) | 6 (4%) | 2 (1%) | 0.21 |
 | Chronic respiratory disease | 3 (1%) | 0 (0%) | 2 (1%) | 0.22 |
 | Cardiovascular disease | 12 (4%) | 4 (2%) | 8 (6%) | 0.16 |
 | Chronic renal failure | 18 (6%) | 12 (7%) | 6 (4%) | 0.23 |